YM-222714
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
We investigated the effects of ketoconazole on the pharmacokinetics (PK) of the direct clotting factor Xa inhibitor darexaban…
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial…
BACKGROUND
Darexaban is a potent direct factor Xa (FXa) inhibitor developed for prophylaxis of venous and arterial thromboembolic…
Darexaban maleate is a novel oral direct factor Xa inhibitor. Darexaban glucuronide (YM-222714) was the major component in plasma…
Inhibitors of factor Xa (FXa), a crucial serine protease in the coagulation cascade, have attracted a great deal of attention as…
Abstract 4393
Background: YM150, a potent oral direct factor Xa (FXa) inhibitor, is in development for the prevention of venous…